Reteplase is a potent thrombolytic agent which is widely used in the management of acute myocardial infarction and stroke. It belongs to the third generation of the thrombolytic drugs and has been derived from native human tissue plasminogen activator by removing three domains of it and keeping the Kringle 2 and Serine protease domains. However, the high cost of this drug, has limited the appli...

AIMS To evaluate the relationship between activated partial thromboplastin time (aPTT) and clinical outcomes in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-V) trial comparing standard-dose reteplase to half-dose reteplase and abciximab. METHODS AND RESULTS We analysed data on 11,420 patients receiving unfractionated heparin. Peak aPTT levels recorded during the hosp...

Cardiovascular disorders are the major cause of concern in India with estimated mortality reaching approximately 64 million by 2015. Though two major treatment options i.e. primary angioplasty (PAMI) and intravenous thrombolysis are available for the management of ST elevation myocardial infarction (STEMI), primary angioplasty is not feasible for majority of STEMI patients in India, hence early...

Abbreviations: APTT 5 activated partial thromboplastin time; ASSENT 5 Asessment of the Safety and Efficacy of a New Thrombolytic Agent; CI 5 confidence interval; FTT 5 Fibrinolytic Therapy Trialists’ Collaborative Group; GISSI 5 Gruppo Italiano per lo Studio Streptokinasi nell’Infarto Miocardico; GP 5 glycoprotein; GUSTO 5 Global Utilization of Streptokinase and TPA (alteplase) for Occluded Cor...

Background: Acute myocardial infarction (AMI) is the leading cause of death throughout the world. One of the standard approaches to treatment of AMI is fibrinolysis. The study was conducted to evaluate the clinical efficacy of tenecteplase versus reteplase through network meta-analysis for AMI. Methods: Randomized trials were comprehensively searched in PubMed, Scopus, Cochrane library, a...

Several studies since 1998 have shown the efficacy of catheter-directed thrombolytic therapy with reteplase. Reteplase is a plasminogen activator that penetrates the thrombus and causes lysis. This catheter-directed approach has been used to treat both arterial and venous occlusions, with a success rate of 72% to 88%. The most serious complication associated with thrombolytic therapy is intracr...

Background: Acute myocardial infarction (AMI) is the leading cause of death throughout the world. One of the standard approaches to treatment of AMI is fibrinolysis. The study was conducted to evaluate the clinical efficacy of tenecteplase versus reteplase through network meta-analysis for AMI. Methods: Randomized trials were comprehensively searched in PubMed, Scopus, Cochrane library, a...